Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

Jan de Jong; Peter Hellemans; James Juhui Jiao; Yuhan Huang; Sofie Mesens; Juthamas Sukbuntherng; Daniele Ouellet

doi:10.1007/s00280-017-3490-7

Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

Cancer Chemother Pharmacol. 2018 Feb;81(2):423. doi: 10.1007/s00280-017-3490-7.

Authors

Jan de Jong¹, Peter Hellemans², James Juhui Jiao³, Yuhan Huang⁴, Sofie Mesens², Juthamas Sukbuntherng⁵, Daniele Ouellet⁶

Affiliations

¹ Janssen Research and Development, LLC, San Diego, CA, USA. JDejong1@its.jnj.com.
² Janssen Research and Development, LLC, Beerse, Belgium.
³ Janssen Research and Development, LLC, Raritan, NJ, USA.
⁴ Janssen Research and Development, LLC, Shanghai, China.
⁵ Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
⁶ Janssen Research and Development, LLC, Spring House, PA, USA.

PMID: 29214363
DOI: 10.1007/s00280-017-3490-7

Abstract

The author would like to correct the affiliations and conflict of interest in the publication of the original article. The corrected details are given below for your reading.

Publication types

Published Erratum